Sablich Kim 4
4 · Eiger BioPharmaceuticals, Inc. · Filed Apr 23, 2021
Insider Transaction Report
Form 4
Sablich Kim
Director
Transactions
- Award
Stock Option (right to buy)
2021-04-23+25,000→ 25,000 totalExercise: $8.43Exp: 2031-04-22→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The option vests in equal monthly installments over 36 months measured from April 23, 2019 subject to Reporting Person's continuous service status as of each such date.